<DOC>
	<DOC>NCT01886300</DOC>
	<brief_summary>This prospective, multicenter, observational study will evaluate the sustained response in patients with HBeAg positive chronic hepatitis B who are treated with Pegasys according to standard of care and in line with the current local labeling in routine clinical practice in Vietnam. Eligible patients will be followed for the duration of their treatment and for up to 2 years thereafter.</brief_summary>
	<brief_title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age HBeAgpositive serologically proven chronic hepatitis B with or without cirrhosis Elevated serum ALT &gt; ULN (upper limit of normal) but &lt;/= 10 x ULN Patients with no contraindications to Pegasys therapy as detailed in the label Written informed consent where local regulations allow or require it Patients should not receive concomitant therapy with telbivudine Coinfection with hepatitis A, hepatitis B or HIV Pregnant or breastfeeding women Patients with depression/mental diseases Neutrophil at baseline &gt; 90.000/mm3 Abnormal T4 or TSH</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>